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Elevated expression of the c-Myc transcription factor
occurs frequently in human cancers and is associ-
ated with tumor aggression and poor clinical
outcome. The effect of high levels of c-Myc on global
gene regulation is poorly understood but is widely
thought to involve newly activated or repressed
‘‘Myc target genes.’’ We report here that in tumor
cells expressing high levels of c-Myc the transcrip-
tion factor accumulates in the promoter regions of
active genes and causes transcriptional amplifica-
tion, producing increased levels of transcripts within
the cell’s gene expression program. Thus, rather than
binding and regulating a new set of genes, c-Myc
amplifies the output of the existing gene expression
program. These results provide an explanation for
the diverse effects of oncogenic c-Myc on gene
expression in different tumor cells and suggest that
transcriptional amplification reduces rate-limiting
constraints for tumor cell growth and proliferation.INTRODUCTION
MYC is a potent oncogene that can promote tumorigenesis in
a wide range of tissues (Felsher and Bishop, 1999; Flores
et al., 2004; Jain et al., 2002; Pelengaris et al., 1999; Sodir
et al., 2011; Soucek et al., 2008; Verbeek et al., 1991). MYC is
the most frequently amplified oncogene and the elevated
expression of its gene product, the transcription factor c-Myc,
correlates with tumor aggression and poor clinical outcome (Ber-
oukhim et al., 2010; Nesbit et al., 1999). Elevated expression of
c-Myc occurs through multiple mechanisms in tumor cells,
including gene amplification, chromosomal translocation, single
nucleotide polymorphism in regulatory regions, mutation of
upstream signaling pathways, and mutations that enhance the
stability of the protein (Eilers and Eisenman, 2008; Meyer and
Penn, 2008; Pomerantz et al., 2009; Wright et al., 2010). Despite56 Cell 151, 56–67, September 28, 2012 ª2012 Elsevier Inc.considerable study, it is not yet clear how elevated levels of
c-Myc reprograms cells to promote the cancer state.
In normal cells, c-Myc links growth factor stimulation and
cellular proliferation (Dang, 2012; Eilers and Eisenman, 2008;
Meyer and Penn, 2008). Mitogenic growth factor signaling
inducesMYC expression, and c-Myc is thought to enhance tran-
scription of proliferation-associated genes (Dang, 2012; Eilers
and Eisenman, 2008; Meyer and Penn, 2008). In tumor cells
that express high levels of c-Myc, cellular proliferation is no
longer dependent on growth-factor stimulation, and this uncou-
pling from growth factor regulation leads to the uncontrolled
proliferation characteristic of cancer cells. Elevated expression
of c-Myc also causes changes in chromatin structure, ribosome
biogenesis, metabolic pathways, cell adhesion, cell size,
apoptosis, and angiogenesis, among others (Amati et al., 1998;
Amati et al., 2001; Cole and Cowling, 2008; Cowling and Cole,
2010; Dai and Lu, 2008; Dang, 2010; Eilers and Eisenman,
2008; Facchini and Penn, 1998; Gallant, 2005; Hanahan and
Weinberg, 2011; Herold et al., 2009; Hoffman and Liebermann,
2008; Hurlin and Dezfouli, 2004; Kuttler and Mai, 2006; Lin
et al., 2009; Meyer and Penn, 2008; Nieminen et al., 2007; Nils-
son and Cleveland, 2003; Peterson and Ayer, 2011; Prochownik,
2008; Ruggero, 2009; Secombe et al., 2004; Shchors and Evan,
2007; Singh and Dalton, 2009; van Riggelen et al., 2010). How
elevated levels of c-Myc cause such a broad spectrum of cellular
effects is not understood.
c-Myc’s identity as a DNA-binding transcription factor
suggests that the set of genes that are bound and regulated by
the factor are key to explaining much of c-Myc’s role in cancer.
c-Myc is a basic helix loop helix (bHLH) transcription factor that
forms a heterodimer with Max and binds to E-box sequences
near the core promoter elements of actively transcribed genes
(Blackwood and Eisenman, 1991). Numerous studies have iden-
tified c-Myc target genes in a variety of tumor cells (Dang et al.,
2006; Ji et al., 2011; Kim et al., 2006; Schlosser et al., 2005;
Schuhmacher et al., 2001; Zeller et al., 2003). Interestingly, these
‘‘c-Myc target signatures’’ show little overlap (Chandriani et al.,
2009), which has made it difficult to ascribe c-Myc’s oncogenic
properties to any one set of target genes. The relatively small set
of genes that are common to c-Myc target signatures are
generally involved in core proliferation and metabolism pro-
cesses (Ji et al., 2011) but do not account for the wide variety
of cellular effects ascribed to oncogenic c-Myc.
Some studies suggest that c-Myc may play a different role
than conventional transcription factors. Although many tran-
scription factors activate gene expression by recruiting the tran-
scription apparatus to promoters, studies in embryonic stem
cells argue that c-Myc binds the core promoter region of a large
fraction of actively transcribed genes and functions to enhance
transcription elongation (Rahl et al., 2010). In tumor cells, there
is evidence that c-Myc can function to stimulate transcription
elongation at certain genes (Bouchard et al., 2004; Bre`s et al.,
2009; Eberhardy and Farnham, 2001, 2002; Gargano et al.,
2007; Kanazawa et al., 2003). These findings led us to consider
the possibility that in tumor cells expressing high levels of
c-Myc, the factor binds most actively transcribed genes and
causes increased expression of all of these genes, as opposed
to the prevailingmodel that it regulates a specific cohort of target
genes.
We describe here how c-Myc occupies and regulates genes
throughout the genome in tumor cells that express various levels
of this oncoprotein. In tumor cells expressing low levels of
c-Myc, the transcription factor is bound almost exclusively to
E-box sequences in the core promoter elements of most actively
transcribed genes. In tumor cells with elevated levels of c-Myc,
we find the transcription factor at the same set of active genes,
but now at elevated levels, occupying both the core promoters
and the enhancers of these active genes at additional, low-
affinity E-box-like sequences. The increase in c-Myc occupancy
leads to increased transcription elongation by RNApolymerase II
(RNA Pol II) and increased levels of transcripts per cell. We
conclude that high levels of c-Myc in tumor cells causes tran-
scriptional amplification, producing elevated levels of transcripts
from the existing gene expression program of tumor cells.
RESULTS
Increased c-Myc Leads to Increased Binding
to Promoters of Active Genes
To investigate the effects of increased levels of c-Myc on its
genome wide occupancy and on gene expression, we used
the human P493-6 B cell model of Burkitt’s lymphoma (Pajic
et al., 2000; Schuhmacher et al., 1999). In these cells, which
contain a tetracycline (Tet)-repressible MYC transgene, MYC
expression can be reduced to very low levels and then reacti-
vated such that the levels of c-Myc protein gradually increase
(Figures 1A and 1B). The P493-6 cells contained 13,000,
76,500, and 362,000 molecules of c-Myc/cell at 0, 1, and
24 hr, respectively, after induction (Figure 1C), and the majority
of this protein accumulated in the nucleus (Figure 1D; Figure S1A
available online).
To investigate the relationship between c-Myc levels and c-
Myc genome occupancy in P493-6 cells, we used chromatin
immunoprecipitation coupled to high-throughput sequencing
(ChIP-Seq) with antibodies specific for c-Myc at 0, 1, and 24 hr
after MYC induction. Previous studies have shown that c-Myc
tends to occupy the promoter regions of protein-coding genes
(Chen et al., 2008; Fernandez et al., 2003; Guccione et al.,2006; Kidder et al., 2008; Li et al., 2003; Rahl et al., 2010; Zeller
et al., 2006), so we focused our initial analysis on the 2 kb regions
surrounding the transcription start sites of such genes. The
results showed that c-Myc generally occupies the core
promoters of actively transcribed genes, as evidenced by co-
occupancy with RNA Pol II (Figure 1E). Furthermore, increased
levels of c-Myc led to increased c-Myc signal at the core
promoters of these genes, as evidenced by inspection of indi-
vidual gene tracks and genome-wide analysis (Figures 1E–1H).
Interestingly, the effect of increasing c-Myc levels by 28-fold in
this system had only a small effect on the total number of genes
that were bound by c-Myc or the total number that were actively
transcribed (Figure 1I, Table S1). Instead, the predominant effect
of increased levels of c-Myc was increased binding to the
promoters of the same set of active genes.
The DNA binding and transcriptional activities of c-Myc
require heterodimerization with Max (Blackwood and Eisenman,
1991; Blackwood et al., 1992; Prendergast et al., 1991), so all
sites bound by c-Myc should be bound by Max. Indeed, ChIP-
seq analysis revealed that Max co-occupied essentially all
c-Myc-bound promoter sites (Figure S1B). Furthermore, analysis
of the c-Myc binding sites at core promoters revealed these
sequences are highly enriched for the known c-Myc/Max
E-box binding motif (CACGTG) (p value < 1 3 10–232). These
results indicate that increased expression of c-Myc in P493-6
cells leads to increased binding by c-Myc/Max heterodimers at
the E-box-containing core promoter sequences of actively tran-
scribed genes.
Increased c-Myc Leads to Enhancer Binding
A search for c-Myc binding events outside the core promoter
regions of protein-coding genes revealed that enhancers associ-
ated with active genes became occupied by c-Myc in cells with
elevated levels of the factor (Figure 2). It was also evident that
rRNA and tRNA genes became occupied by c-Myc (Figure 2A),
as reported previously (Arabi et al., 2005; Gomez-Roman et al.,
2003; Grandori et al., 2005). c-Myc was not enriched at tran-
scriptionally silent genes (genes lacking evidence of RNA Pol II)
in cells with low or high levels of the factor.
Increases in the levels of c-Myc led to substantial increases in
its levels at enhancers of active genes (Figures 2B and 2C;
Figures S2A and S2B). As expected, the c-Myc heterodimer
partner, Max, occupied essentially all the enhancer sites that
were bound by c-Myc (Figure S2C). Analysis of the sequences
at enhancer elements revealed that an E-box variant motif is
highly enriched at these sites (p value < 4 3 10-775) (Figure 2D).
These results are consistent with the expectation that c-Myc
occupies the E-box variant sequences at enhancers as a
c-Myc/Max heterodimer.
In cells expressing high levels of c-Myc, the number of mole-
cules of the factor (362,000) exceeds the number of active
core promoters (16,500). We reasoned that E-box sequences
in core promoter regions would therefore become saturated as
the levels of c-Myc increased, and the factor would then bind
lower affinity E-box sequences that occur at core promoters
and enhancers. To test this idea, we ranked all E-box (CANNTG)
variants present in core promoter and enhancer regions by
c-Myc binding signal in the 24 hr ChIP-Seq data, and determinedCell 151, 56–67, September 28, 2012 ª2012 Elsevier Inc. 57
Figure 1. c-Myc Overexpression Leads to
Increased Binding at Promoters of Active
Genes
(A) Schematic of the inducible c-Myc expression
system in P493-6 Burkitt’s lymphoma cells.
(B) Western blot of relative levels of c-Myc protein
(top) and actin (bottom) at 0, 1, and 24 hr after
induction.
(C) Left: Quantitative Western blot of c-Myc during
induction. Increasing amounts of purified, re-
combinant his6-c-Myc (left lanes) and lysates
prepared from increasing numbers of cells (right
lanes) shown at 0 (top), 1 (middle), and 24 hr
(bottom). Right: Coomasie stained gel of purified
recombinant his6-c-Myc.
(D) Images of three representative cells taken
during c-Myc induction. From left to right, cells at
0, 1, and 24 hr are shown. From top to bottom are
images of bright field, CD9 stained, DAPI stained,
c-Myc stained, and a merge of c-Myc and Dapi
stained cells.
(E) Median c-Myc levels in the ±1 kb region around
transcription start sites (TSSs) of promoters
ranked by increasing RNAPol II occupancy at 0 hr.
Levels are in units of reads per million mapped
reads per base pair (rpm/bp) for 0, 1, and 24 hr
(blue, black, red). Promoters were binned (50/bin)
and a smoothing function was applied to median
levels.
(F) Gene tracks of c-Myc binding at the NPM1
gene at 0 (top), 1 (middle), and 24 hr (bottom). The
x axis shows genomic position. The y axis shows
signal of c-Myc binding in units of rpm/bp.
(G) Heatmap of c-Myc levels at TSS regions at 0, 1,
and 24 hr. Each row shows the ±5 kb centered on
the TSS. TSSs for all actively transcribed genes in
P493-6 cells are shown and ranked by c-Myc
occupancy at 0 hr. Color scaled intensities are in
units of rpm/bp.
(H) Boxplots of c-Myc levels at 0, 1, and 24 hr in
the ±1 kb centered on the TSS of all genes actively
transcribed at the start of c-Myc induction. Units
are in rpm/bp. Changes between mean c-Myc
levels at promoters are significant (Welch’s two-
tailed t test) between 0 and 1 hr (p value < 13 10-16)
and 1 and 24 hr (p value < 1 3 10-16).
(I) Venn diagram showing the overlap between
sets of transcribed genes during c-Myc induction
at 0, 1, and 24 hr. Transcribed genes were defined
as having an enriched region for either H3K4Me3
or RNA Pol II within 5 kb of the annotated tran-
scription start site (TSS). Each circle represents
the set of transcribed genes at 0 (blue), 1 (black), or
24 hr (red). See also Figure S1.how frequently these various sequences were present in these
bound regions (Figure 2E). We found that the highest signals
were associated with the canonical CACGTG E-box sequence
and that the canonical E-box sequence occurs with the highest
frequency (40%) of all E-box sequences in core promoter
regions (Figure 2E). In contrast, the canonical E-box sequence
occurs much less frequently in enhancer regions (15%), where
a variety of E-box variants are occupied by c-Myc. To investigate58 Cell 151, 56–67, September 28, 2012 ª2012 Elsevier Inc.whether there is a relationship between the c-Myc signal at
various E-box sequences in the ChIP-Seq data and c-Myc
binding affinity for such sequences, we produced recombinant
c-Myc/Max protein and studied its binding to DNA fragments
containing E-box sequences in vitro by using a gel shift assay
(Figure 2F, Figure S2D). The relative affinity of binding to canon-
ical and variant E-box sequences was investigated by incubating
c-Myc/Max protein with a DNA fragment containing the
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Figure 2. c-Myc Overexpression Leads to Binding of Active Enhancers
(A) Heatmap showing c-Myc occupancy levels at the top 5,000 promoters ranked by RNA Pol II levels at 0 hr, the top 5,000 active enhancers ranked by H3K27Ac
levels at 0 hr, rRNA genes, and tRNA genes (columns) at 0, 1, and 24 hr (rows). Intensities are in units of c-Myc rpm/bp.
(B) Heatmap of H3K27Ac and c-Myc levels at the top 5,000 active enhancers ranked by H3K27Ac levels at 0 hr in P493-6 cells at 0 and 24 hr. Each row shows
±5 kb centered on the H3K27Ac peak. Rows are ordered by the net increase in c-Myc occupancy after 24 hr of c-Myc induction. Color scaled intensities are in
units of rpm/bp.
(C) Boxplots of c-Myc levels at 0, 1, and 24 hr in the ±1 kb around the center of the top 5,000 active enhancers ranked by H3K27Ac levels at the start of c-Myc
induction. Units are in rpm/bp. Changes betweenmean c-Myc levels at enhancers are significant (Welch’s two-tailed t test) between 0 and 1 hr (p value < 13 10-16)
and 1 and 24 hr (p value < 1 3 10-16).
(D) c-Myc binding motif found enriched at core promoters (left, p value < 1 3 10-232) or at active enhancers (right, p value < 4 3 10-775) 24 hr after c-Myc
induction.
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canonical E-box in competition with three different DNA frag-
ments. The canonical E-box sequence was the most effective
in the competition assay, the E-Box 3 variant CATGTG was
less effective, and the E-Box 1 variant CAATTG was least effec-
tive (Figure 2F). Thus, for these three E-box sequences, the rela-
tive binding signals obtained by ChIP-Seq reflect the relative
affinities in this in vitro binding assay. These results are consis-
tent with the model that c-Myc/Max occupies high affinity
E-box sequences at core promoters when the protein is present
at low levels but then occupies lower affinity E-box sequences at
core promoters and enhancers when present at high levels
(Figure 2G).
High c-Myc Expression Causes Transcriptional
Amplification in Tumor Cells
Previous studies have shown that c-Myc binding can recruit
Positive Transcription Elongation Factor b (P-TEFb) and thereby
enhance elongation by RNA Pol II at the CAD and CCND2 genes
in tumor cells (Bouchard et al., 2004; Eberhardy and Farnham,
2001) and at a large fraction of active genes in embryonic stem
cells (Rahl et al., 2010). We therefore investigated whether the
elevated levels of c-Myc have these effects at active genes in
P493-6 tumor cells.
We first investigated whether increased c-Myc occupancy
leads to increased recruitment of the P-TEFb elongation
complex genome-wide. At core promoters and enhancers that
experienced increased c-Myc occupancy, we detected a signifi-
cant increase in occupancy by Cdk9, the catalytic subunit of P-
TEFb (Figure 3A). For comparison, the levels of the transcription
initiation-associated histone H3K4me3 modification showed
little or no change at these genes.
We then investigated whether increased c-Myc occupancy
results in stimulation of RNA Pol II elongation through increased
P-TEFb activity. P-TEFb predominantly phosphorylates the
second serine residue of the RNA Pol II C-terminal domain
heptad repeat (Zhou et al., 2012). The levels of this elongation-
associated Ser2-phosphorylated RNA Pol II (Ser2) and the initia-
tion-associated Ser5-phosphorylated RNA Pol II (Ser5) were
measured in P493-6 cells expressing increasing levels of
c-Myc (Figure 3B). The levels of the Ser2 RNA Pol II increased
2-fold over the 24 hr time course, whereas the levels of Ser5
RNA Pol II remained largely unchanged, indicating an increase
in actively elongating enzyme in cells with increased levels of
c-Myc. In addition, we found that increased c-Myc occupancy
results in a general and significant increase in the proportion of
elongating to initiating RNA Pol II across the genome as(E) c-Myc occupancy at E-box sequences. Left: E-box variants (CANNTG) were ra
the canonical CACGTG E-box is indicated by the shaded color intensity adjacent
bound regions at promoters (red) or enhancers (blue) for all E-box variants.
(F) Gel shift assays of purified c-Myc/Max binding to canonical CACGTG E-box s
excess) of unlabeled competitor sequences. The higher bands reflect the amoun
band reflects the amount of unbound canonical E-box DNA. Lane 1: No competit
fragments containing the canonical E-box or variant E-box sequence motifs (E-b
around the E-box (bold). Differences from the canonical sequence are highlighte
(G) Gene tracks showing c-Myc occupancy (rpm/bp) at the NNT promoter (left) o
c-Myc induction. The x axis shows genomic position. The y axis shows signal s
promoter or enhancer are depicted as boxes shaded by E-box signal strength (from
boxes). See also Figure S2.
60 Cell 151, 56–67, September 28, 2012 ª2012 Elsevier Inc.measured by ChIP-Seq enrichment (Figure 3C) and traveling
ratio (p value < 1 3 10-5) (Figure 3D). As expected, genes with
increased c-Myc occupancy at enhancers displayed the great-
est increases in elongating RNA Pol II levels (Figure S3A). These
results indicate that increased c-Myc binding at active genes
stimulates RNA Pol II elongation.
Finally, we determined whether increased c-Myc occupancy
results in increases in the absolute levels of RNA. We found
that there was a 1.5-fold increase in total RNA levels in cells
over the time course of c-Myc induction (Figure 3E). Both rRNA
and tRNA levels were increased (Figure 3E; Figure S3B). Digital
gene expression (NanoString) (Geiss et al., 2008) was used to
quantify mRNA levels/cell for a large set of 1,388 genes selected
from multiple functional categories. The results showed that
transcripts from 96% of genes that were expressed at reliable
levels (one transcript/cell or higher) in cells with relatively low
levels of c-Myc were upregulated upon c-Myc induction, with
an average 2.4-fold increase in expression (Figure 3F). In
contrast, genes that were not expressed in cells with lower levels
of c-Myc remained silent (Figure 3F). These results are remark-
ably consistent with the result, described above, that increasing
the levels of c-Myc results in increased binding to the set of ex-
isting active genes, with negligible binding to new sets of genes.
Together, these results indicate the predominant effect of
substantially elevated levels of c-Myc is amplified transcription
of the existing gene expression program.
c-Myc Genome Occupancy in Diverse Tumor Cells with
Elevated c-Myc
The c-Myc inducible Burkitt’s lymphoma model revealed that
elevated levels of c-Myc result in increased binding to core
promoters and enhancers of active genes, leading to transcrip-
tional amplification. To determine whether high levels of c-Myc
leads to similar binding behavior in diverse patient-derived tumor
cells, we studied cell lines derived from three different clinically
relevant tumor types: small cell lung carcinoma (SCLC), multiple
myeloma (MM), and glioblastoma multiforme (GBM). The cell
lines used were H2171 (SCLC) (Johnson et al., 1987), which
has a c-Myc gene amplification, MM1.S (MM) (Shou et al.,
2000), which has an IGH-MYC translocation, and U-87 MG
(GBM) (Hirvonen et al., 1994), in which c-Myc levels accumulate
due to enhanced expression. The levels of c-Myc in these cells
were 880,000 molecules/cell in H2171 (SCLC), 495,000 mole-
cules/cell in MM1.S (MM), and 110,000 molecules/cell in U-87
MG (GBM) (Figure 4A), which are similar to the levels observed
in the c-Myc inducible Burkitt’s lymphoma model between 1nked by c-Myc ChIP-Seq signal strength at 24 hr. The signal strength relative to
to E-box sequences. Right: The percentage of all E-box motifs found in c-Myc
equences following competition with decreasing amounts (5-, 2.5-, and 1-fold
ts of labeled canonical E-box sequences bound by c-Myc/Max and the lower
or DNA. Lanes 2–10: The effect of adding various amounts of competitor DNA
ox 1 and E-box 3). Bottom: Competitor DNA sequences are shown centered
d in red.
r downstream enhancer (right) after 0 (top), 1 (middle), and 24 hr (bottom) after
trength of c-Myc binding. E-boxes proximal to the c-Myc peak at either the
Figure 2E). TheNNT gene is indicated at the bottom (introns as lines, exons as
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Figure 3. c-Myc Overexpression Leads to
Transcriptional Amplification
(A) Boxplots of the fold changes in levels of
H3K4Me3 (green) and Cdk9 (pink) between 24 hr
and 0 hr at the top 2,000 core promoters with the
highest increased c-My occupancy during c-Myc
induction (left), the top 2,000 enhancers with the
highest increased c-Myc occupancy during c-Myc
induction (center), and 2,000 enhancers without
increased c-Myc occupancy during c-Myc induc-
tion (right). The differences in the levels of changes
between H3K4Me3 and Cdk9 were significant
(Welch’s two-tailed t test) at core promoters
(p value < 2.2 3 10-16) and at enhancers with
increased c-Myc occupancy (p value = 6.483 10-7)
and not significant at enhancers without increased
c-Myc occupancy (p value = 0.06).
(B) Western blots of RNA Pol II at 0, 1, and 24 hr
using antibodies specific to various forms of the
enzyme. From top to bottom: RNA Pol II Ser2P
specific (H5, Covance), RNA Pol II Ser2P specific
(A300-654A, Bethyl), RNA Pol II Ser5P specific
(H14, Covance), hypophosphorylated RNA Pol II
specific (8WG16, Bethyl), total RNA Pol II (N-20,
Santa Cruz). For RNA Pol II Ser2P and Ser5P
antibodies, the ratio of signals versus 0 hr is dis-
played for each time point below the blot.
(C) Bar graph of mean ± SEM. RNA Pol II enrich-
ment ratio between elongating and initiating
regions during c-Myc induction at 0, 1, and 24 hr
(left, center, and right) for the top 5,000 genes
ranked by RNA Pol II occupancy at 0 hr. The y axis
shows the ratio between the fold enrichment over
background of RNA Pol II in the elongating region
versus the fold enrichment over background of
RNA Pol II in the promoter region. Changes
between 0, 1, and 24 hr are significant (Welch’s
two-tailed t test, p value < 1 3 10-16).
(D) Empirical cumulative distribution plots of RNA
Pol II traveling ratios (TR) for 1,000 transcribed
genes (Rahl et al., 2010). Genes were randomly
selected from the pool of genes containing higher than background levels of RNA Pol II at the promoter and gene body at 0, 1, and 24 hr. Differences in the TR
distribution at 0 and 24 hr are significant (Welch’s two-tailed t test, p value = 4.5 3 10-5).
(E) Left: Bar graph showing quantification of total RNA levels for cells at 0, 1, and 24 hr. Units are in ng of total RNA per 1,000 cells and represented as mean ±
SEM. Right: 5% TBE urea gel of ethidium bromide stained total RNA extracted from equivalent numbers of cells at 0, 1, and 24 hr. Bands corresponding to the
5.8S rRNA subunit, 5S rRNA subunit, and tRNA are labeled.
(F) Boxplot of transcripts/cell estimations from NanoString nCounter gene expression assays for active (right) or silent (left) genes at 0, 1, and 24 hr; 755 active
genes (expressed > 1 transcripts/cell) at 0 hr are shown (left, red). 514 silent genes (expressed < 0.5 transcripts/cell) at 0 hr are shown (right, black). The number
of genes with increased expression between 0 and 1 hr are significant (Wilcoxon rank sum test) for active genes (p value < 2.23 10-16) and nonsignificant for silent
genes (p value = 0.997). See also Figure S3.and 24 hr after induction (Figure 1). ChIP-Seq analysis revealed
that c-Myc occupies both the core promoters and enhancers
of actively transcribed genes in all three tumor types (Figures
4B–4D). Inspection of individual genes tracks showed c-Myc
binding to the core promoters of individual genes and to active
enhancers in the respective cell type (Figure 4E). For all three
tumor types, the c-Myc binding sites at core promoters occurred
at canonical E-box motifs, whereas c-Myc binding at enhancers
occurred at variant E-box sequence motifs (Figure 4F). We
conclude that in diverse tumor cells expressing elevated levels
of c-Myc, the transcription factor consistently occupies sites at
the promoters and enhancers of the majority of actively tran-
scribed genes.Effects of Differential c-Myc Expression in SCLC
MYC amplification in SCLC correlates with tumor progression
and often occurs in association with recurrent disease (Johnson
et al., 1987; Little et al., 1983). We used two different SCLC lines
that express different levels of c-Myc to determine whether
higher c-Myc levels are associated with increased promoter/
enhancer occupancy and transcriptional amplification in
patient-derived SCLC. H128 SCLC cells express relatively low
levels of c-Myc from an unamplified MYC gene and H2171
SCLC cells express high levels of c-Myc due to amplification
of a region on chromosome 8 with MYC (Campbell et al.,
2008). Although these cells originate from different patients,
they nonetheless provide a system to determine if the effectsCell 151, 56–67, September 28, 2012 ª2012 Elsevier Inc. 61
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of different levels of c-Myc observed in the Burkitt’s lymphoma
model are recapitulated by low and high endogenous expression
in SCLC.
Analysis of the steady-state levels of c-Myc in these two SCLC
cell lines revealed that there was approximately 150-fold more c-
Myc protein in H2171 compared to H128 (Figure 5A; Figure S4A).
c-Myc occupancy was associated with RNA Pol II occupancy
genome-wide in both low and high c-Myc SCLC (Figure 5B).
The set of transcribed genes was similar in low and high c-Myc
SCLC, indicating that elevated c-Myc levels do not increase
the number of expressed genes significantly (Figure S4B).
SCLC cells with higher expression of c-Myc showed increased
occupancy of core promoters and enhancers (Figure 5C) of
active genes. Thus, the effects of increased levels of c-Myc on
genome-wide occupancy that were observed in the Burkitt’s
lymphoma model were also observed in the SCLC tumor cells.
We then investigated whether SCLC cells with elevated c-Myc
levels showed evidence of increased transcription elongation.
SCLC cells expressing higher c-Myc levels (H2171) had a higher
ratio of elongation-associated Ser2-phosphorylated RNA Pol II
molecules (Figure 5D), and a small but significant increase in
the levels of elongating RNA Pol II across the genome as
measured by RNA Pol II ChIP-Seq enrichment (Figure 5E) and
by RNA Pol II traveling ratio (Figure 5F). SCLC cells with elevated
c-Myc levels showed increased levels of total RNA, tRNA,
and rRNA (Figure 5G; Figure S4C). Digital gene expression
(NanoString) analysis demonstrated that 88% of genes ex-
pressed at one transcript/cell or higher in low c-Myc cells were
upregulated upon c-Myc induction, with an average 3.5-fold
increase in expression (Figure 5H). In contrast, 93% of genes
that were not expressed in cells with lower levels of c-Myc
remained silent (Figure 5H). As with the inducible c-Myc system,
these results indicate that the predominant effect of elevated
levels of c-Myc in SCLC is transcriptional amplification of the ex-
isting gene expression program.
DISCUSSION
Elevated expression of c-Myc occurs frequently in human
cancers and is associated with tumor aggression and a remark-
able range of cellular phenotypes, but the effect of high levels of
c-Myc on global gene regulation in tumor cells is poorly under-
stood. A widely held view is that high levels of c-Myc lead toFigure 4. c-Myc Binds to Core Promoters and Active Enhancers when
(A) Western blot of c-Myc protein levels in tumor cell lines compared with purified
from increasing numbers of cells (right lanes) are shown for SCLC (left), MM (mid
(B) For each tumor cell line, median c-Myc levels in units of rpm/bp are plotted at p
(50/bin) and a smoothing function was applied to median levels.
(C) For each tumor cell line, a heatmap of c-Myc levels at TSSs of actively transc
TSSs for actively transcribed genes in each tumor cell line are shown. Color sca
(D) For each tumor cell line, a heatmap displays H3K27Ac and c-Myc levels at act
Rows are ordered by H3K27Ac binding in each tumor cell line. Color scaled inte
(E) c-Myc binding at theNOTCH1 promoter in GBM (top), SCLC (middle), andMM
signal of c-Myc occupancy (rpm/bp). The NOTCH1 gene is indicated at the botto
The core promoter of NOTCH1 is boxed in black.
(F) For each tumor cell line, the c-Myc binding motif found enriched at core promot
promoter, p < 43 10-215; SCLC active enhancer, p < 93 10-1504; MM core promot
1 3 10-160; GBM active enhancer p < 4 3 10-635).newly activated or repressed ‘‘Myc target genes.’’ The results
described here and by Nie et al. (2012) in this issue, support
a different model: c-Myc accumulates in the promoter regions
of active genes across the cancer cell genome and causes tran-
scriptional amplification, producing increased levels of tran-
scripts within the cell’s gene expression program.
Transcription factors such as the myogenic regulator MyoD or
the pluripotency regulators Oct4 and Sox2, when newly ex-
pressed at high levels in cells, will bind and establish new
enhancers thatmodify theexpressionprogramandalter cell state
(Graf and Enver, 2009). In contrast, expression of high levels of c-
Myc in tumor cells produces a very different result. In the tumor
cell systems described here, increased levels of c-Myc result in
increased binding to active genes and little binding to genes
that were inactive at low c-Myc levels, and there is little change
in the set of actively transcribed genes. As the levels of c-Myc
increase, high affinity E-box sites at active core promoters
become saturated and lower affinity E-box variant sequences
at promoters and enhancers become occupied. This behavior
of c-Myc is consistent with evidence that the open chromatin
environment at active promoters is important for binding by this
factor (Guccione et al., 2006). Furthermore, enhancers loop into
proximity of core promoters at active genes (Bulger and Grou-
dine, 2011; Go¨ndo¨r and Ohlsson, 2009; Kagey et al., 2010; Ong
and Corces, 2011) and this proximity may facilitate binding of
c-Myc to nearby enhancer elements once binding to sites in
core promoters is saturated. The functional consequence of
elevated c-Myc binding at active genes is increased recruitment
of the pause release factor P-TEFb, increased transcriptional
elongation, and a global increase in transcript levels.
The model in which oncogenic c-Myc acts primarily in tran-
scriptional amplification of the tumor cell’s gene expression
program provides an explanation for the diverse effects of onco-
genic c-Myc on gene expression in different tumor cells.
Numerous gene expression studies have identified sets of genes
whose expression levels are altered by changes in c-Myc levels
(Dang et al., 2006; Ji et al., 2011; Kim et al., 2006; Schlosser et al.,
2005; Schuhmacher et al., 2001; Zeller et al., 2003). These c-Myc
signatures vary greatly across cell types (Chandriani et al., 2009),
making it difficult to ascribe the broad range of cellular effects
produced by oncogenic c-Myc to a key set of target genes.
This variation in c-Myc signatures would be expected with tran-
scriptional amplification of the different gene expressionOverexpressed in Different Cancers
c-Myc. Increasing amounts of purified c-Myc (left lanes) and lysates prepared
dle), and GBM (right).
romoters ranked by increasing RNA Pol II occupancy. Promoters were binned
ribed genes is displayed. Each row represents the ±5 kb centered on the TSS.
led intensities are in units of rpm/bp.
ive enhancers. Each row represents the ±5 kb centered on the H3K27Ac peak.
nsities are in units of rpm/bp.
(bottom) tumor cell lines. The x axis shows genomic position. The y axis shows
m (introns as lines, exons as boxes). Enhancer regions are shaded in light blue.
ers of actively transcribed genes and active enhancers is displayed (SCLC core
er, p < 63 10-117; MM active enhancer, p < 53 10-678; GBM core promoter, p <
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Figure 5. c-Myc Enhancer Invasion and
Transcriptional Amplification in Patient-
Derived Small Cell Lung Carcinoma
(A) c-Myc protein levels in small cell lung carci-
noma for low c-Myc expressing (H128) and c-Myc
overexpressing (H2171) tumor cells determined by
quantitative Western Blot analysis with purified
his6-c-Myc.
(B) For low and high c-Myc SCLC, the median
c-Myc levels in units of rpm/bp were plotted at
promoters ranked by increasing RNA Pol II occu-
pancy in H128. c-Myc levels are shown for H128
and H2171 SCLC (black, red). Promoters were
binned (50/bin) and a smoothing function was
applied to median levels.
(C) Left: Boxplots of c-Myc levels in the ±1 kb
centered on TSSs at promoters of 15,000 actively
transcribed genes in H128 and H2171. Right:
Boxplot representation of c-Myc levels at 15,000
active enhancers in H128 and H2171. Units are in
rpm/bp. Changes between mean c-Myc levels are
significant (Welch’s two-tailed t test) at promoters
(p value < 2.2 3 10-16) and enhancers (p value <
2.2 3 10-16).
(D) Western blots of RNA Pol II in H128 and H2171
cells using antibodies specific to various forms of
the enyzme. From top to bottom: RNA Pol II Ser2P
specific (H5, Covance), RNA Pol II Ser2P specific
(A300-654A, Bethyl), RNA Pol II Ser5P specific
(H14, Covance), hypophosphorylated RNA Pol II
specific (8WG16, Bethyl), total RNA Pol II (N-20,
Santa Cruz). For RNA Pol II Ser2P and Ser5P
antibodies, the ratio of signal versus H128 signal
are displayed for each cell line below the blot.
(E) Bar graph of mean ± SEM. RNA Pol II enrich-
ment ratio between elongating and initiating in
H128 and H2171 cells for the top 5,000 genes
ranked by RNA Pol II occupancy in H128 cells. The
y axis shows the ratio between the fold enrichment
over background of RNA Pol II in the elongating
region versus the fold enrichment over back-
ground of RNA Pol II in the promoter region.
Changes between H128 and H2171 cells
are significant (Welch’s two-tailed t test, p value <
1 3 10-16).
(F) Empirical cumulative distribution plots of Pol II
traveling ratios (TR) for 1,000 transcribed genes.
Genes were randomly selected from the pool of
genes containing higher than background levels of
Pol II at the promoter and gene body in H128 and
H2171 cells. Differences in the TR distribution
between H128 and H2171 are significant (Welch’s
two-tailed t test, p value = 5 3 10-3).
(G) Left: Bar graph showing quantification of total RNA levels for H128 and H2171 cells. Units are in ng of total RNA per 1,000 cells and represented as mean ±
SEM. Right: 5% TBE urea gel of ethidium bromide stained total RNA extracted from equivalent numbers of cells from H128 and H2171. Bands corresponding to
the 5.8S rRNA subunit, 5S rRNA subunit, and tRNA are labeled.
(H) Boxplots of transcripts/cell estimations from NanoString nCounter gene expression assays for active (right) or silent (left) genes in H128 and H2171 cells. 706
active genes (expressed > 1 transcripts/cell) in H128 cells are shown (left, red). 568 silent genes (exrpressed < 0.5 transcripts/cell) in H128 cells are shown
(right, black). The number of genes with increased expression between H128 and H2171 cells are significant (Wilcoxon rank sum test) for active genes (p value <
2.2 3 10-16) and nonsignificant for silent genes (p value = 0.03). See also Figure S4.programs inherent in different cancer cells. Some variation in
c-Myc signatures may also be due to a limitation of microar-
ray-based analysis, which typically involves a normalization
step that assumes similar levels of total RNA and thus does64 Cell 151, 56–67, September 28, 2012 ª2012 Elsevier Inc.not detect amplification of the entire gene expression program.
Although our evidence indicates that c-Myc functions primarily
in amplification, there are a small number of genes whose
expression is reduced in cells with high levels of c-Myc. These
genes may be directly repressed by c-Myc or their repression
may be due to indirect effects; for example, elevated levels of
a negative regulator might overwhelm c-Myc-induced amplifica-
tion of some genes.
Transcriptional amplification may explain why c-Myc plays
a critical role in tumorigenesis in a wide variety of human tissues.
Although numerous cellular pathways can bemutated to provide
an initial signal for increased cell growth and proliferation, tran-
scriptional amplification could provide the sweeping changes
in cellular physiology necessary for aggressive cellular growth
and proliferation. Translational capacity and aerobic energy
metabolism are among the cellular functions that are limiting
for the growth of tumor cells and an increase in the levels of tran-
scripts for this machinery would increase the levels of its rate
limiting components (Dai and Lu, 2008; Ruggero, 2009). It is
also possible that the increase in essentially all components of
the gene expression program provides cells with an advantage
when adapting to the multiple mutated pathways that charac-
terize most tumor cells.
Elevated expression of c-Myc occurs frequently in cancer. The
model that c-Myc can promote tumorigenesis through transcrip-
tional amplification suggests that therapies focused on the
molecular mechanisms involved in RNA Pol II pause control
and elongation may be valuable for clinical treatment of many
different tumors.
EXPERIMENTAL PROCEDURES
Cell Culture
Small-cell lung carcinoma cells H128 (HTB-120 ATCC) and H2171 (CRL-5929)
were kindly provided by John Minna, UT Southwestern and P493-6 cells were
kindly provided byChi VanDang, University of Pennsylvania.Multiplemyeloma
cells MM1.S (CRL-2974 ATCC) and U-87 MG cells (HTB-14 ATCC) were
purchased from ATCC. Unless otherwise stated, all cells were propagated in
RPMI-1640 supplemented with 10% fetal bovine serum and 1% GlutaMAX
(Invitrogen, 35050-061). U-87 MG cells were cultured in Eagle’s Minimum
Essential Medium (EMEM) modified to contain Earles Balanced Salt Solution,
nonessential amino acids, 2 mM L-glutamine, 1 mM sodium pyruvate, and
1,500 mg/l sodium bicarbonate. Cells were grown at 37C and 5% CO2.
For c-Myc induction experiments, the conditional pmyc-tet construct in
P493-6 cells was repressed with 0.1 mg/ml tetracycline (Sigma, T7660) for
72 hr.MYC expression was induced by three washes with RPMI-1640medium
containing 10% tetracycline system approved FBS (Clontech, 631105) and
1% GlutaMAX.
Quantitative Western Blotting
Quantitative western blotting was carried out as previously described (Ru-
dolph et al., 1999). For every protein preparation (total protein extraction),
cell number was determined by counting cells with C-Chip disposable hemo-
cytometers (Digital Bio). Cells were lysed at a concentration of 100,000 cells/ml
lysis buffer and processed as described above. Purified, recombinant full-
length his6-c-Myc was used as a standard and loaded at the concentrations
depicted in each figure. Determination of the number of c-Myc protein mole-
cules per cell was carried out by linear regression analysis using the Image
Lab Software (Bio-Rad, version 3.0).
Protein Purification
Purified his6-c-Myc and his6-Max was generated in BL21(DE3) RIL E. coli
essentially the same as described in (Farina et al., 2004) except c-Myc and
Maxwere purified individually. Constructs were kindly provided by ErnestMar-
tinez (UC Riverside) and his6-c-Myc was subcloned into pET15b prior to puri-
fication. Purified protein was stored as glycerol stocks (40% glycerol, 50 mM
Tris [pH 8.0], 150 mM NaCl) at 80C.c-Myc/Max Gelshift Experiments
Purified recombinant his6-c-Myc and his6-Max were used to test the ability of
c-Myc/Max heterodimers to bind E-box variants in vitro using similar condi-
tions described in (Ecevit et al., 2010). In brief, biotinylated Ebox DNA was
competed with the indicated amounts of nonbiotinylated Ebox variant.
Chromatin Immunoprecipitation
ChIP was carried out as described in Rahl et al. (2010). Antibodies used are as
follows: Total Pol II (Rpb1 N-terminus), Santa Cruz sc-899 lot# B1010; c-Myc
(N-262), Santa Cruz sc-764 lot#G0111; Max (C-17), Santa Cruz sc-197
lot#A0311; Histone H3K27Ac, Abcam ab4729 lot#GR45787-1; Med1, Bethyl
Labs A300-793A lot#A300-793A-1; Histone H3K4me3, Millipore 07-473 lot#-
DAM1824767; and Cdk9, Santa Cruz sc-8338 lot# I0109 and Santa Cruz
sc-484 lot# B0910.
Illumina Sequencing and Library Generation
Purified ChIP DNA was used to prepare Illumina multiplexed sequencing
libraries. Libraries for Illumina sequencing were prepared following the Illumina
TruSeq DNA Sample Preparation v2 kit protocol with the selected exceptions
described in supplemental methods.
Data Analysis
All ChIP-Seq data sets were aligned using Bowtie (version 0.12.2) (Langmead
et al., 2009) to build version NCBI36/HG18 of the human genome. Aligned and
raw data can be found online associated with the GEO Accession ID
GSE36354.
We used a simple method to calculate the normalized read density of
a ChIP-Seq data set in any region. ChIP-Seq reads aligning to the region
were extended by 200 bp and the density of reads per base pair (bp) was
calculated. The density of reads in each region was normalized to the total
number of million mapped reads producing read density in units of reads
per million mapped reads per bp (rpm/bp).
We used the MACS version 1.4.1 (Model based analysis of ChIP-Seq)
(Zhang et al., 2008) peak finding algorithm to identify regions of ChIP-Seq
enrichment over background. A p value threshold of enrichment of 1 3 10-9
was used for all data sets. In order to display c-Myc binding at promoters,
we first calculated the c-Myc ChIP-Seq density (rpm/bp) in 50 bp bins ±
5 kb around the transcription start site (TSS) of transcribed genes. Promoters
were ranked by average c-Myc density and the c-Myc density in each bin was
shaded based on intensity. In order to quantify changes in c-Myc occupancy at
promoters, the mean ChIP-Seq density in units of rpm/bp was calculated for
the ±1 kb region around the TSS of transcribed genes. The distribution of
mean ChIP-Seq densities was compared between samples using a Welch’s
two-tailed t test. A similar approach was used to quantify c-Myc binding at
enhancers, where instead of centering regions on the TSS, the center of the
enriched region for H3K27Ac was used. Active enhancers were defined as
regions of enrichment for H3K27Ac outside of promoters (greater than 5 kb
away from any TSS).
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, four
figures, and five tables and can be found with this article online at http://dx.
doi.org/10.1016/j.cell.2012.08.026.
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